Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 29, 2015 10:38 AM ET

Biotechnology

Company Overview of Ironwood Pharmaceuticals, Inc.

Executive Profile

Mark A. Peterson

AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.

----

Background

Mr. Mark A. Peterson served as the President of Ironwood Pharmaceuticals Inc. (formerly Microbia, Inc.) Mr. Peterson also served as President of Fidelity Biosciences Group at Fidelity Investments. Prior to assuming this responsibility, he served as President of Fidelity Corporate Systems and Processing, where he oversaw the delivery of a group of internal corporate services company-wide. Mr. Peterson also served as President of Fidelity Technology and Processing Group ...

Corporate Headquarters

301 Binney Street
Cambridge, Massachusetts 02142

United States

Phone: 617-621-7722
Fax: 617-494-0480

Board Members Memberships

Former Director
Former Director
Former Director

Education

Bachelor's Degree
Pennsylvania State University
JD
Temple University School Of Law

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$557.2K
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$860.0K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$555.7K
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
$440.2K
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
$650.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ironwood Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.